Purpose. Despite the long history of pertussis vaccination and high vaccination coverage in Poland and many other developed countries, pertussis incidence rates have increased substantially, making whooping cough one of the most prevalent vaccine-preventable diseases. Among the factors potentially involved in pertussis resurgence, the adaptation of the Bordetella pertussis population to country-specific vaccine-induced immunity through selection of non-vaccine-type strains still needs detailed studies.
INTRODUCTION
Bordetella pertussis is a Gram-negative bacterium that causes a highly contagious infectious respiratory disease in humans, known as pertussis or whooping cough. Despite widespread pertussis vaccination and the high pertussis vaccine coverage in industrialized countries, whooping cough is still recognized as public health problem. The first signs of the resurgence of pertussis in populations maintaining high vaccination coverage were observed in the 1990s [1] . Since then, pertussis has unfortunately become the most widespread vaccine-preventable disease in developed countries [2] [3] [4] .
In Poland, children have been continuously immunized since 1960, with three primary doses and one booster dose at 2, 3-4, 5-6 and 16-18 months of life with a nationally produced whole-cell diphtheria-tetanus-pertussis (DTP) vaccine. The vaccine strain composition of the whole-cell pertussis (wP) component of the Polish DTP vaccine has changed over time. Until 1967, as many as 14 strains may have been used for vaccine production and these were differently allocated into particular vaccine lots. Ten of 14 previously used vaccine strains have been withdrawn, and one new strain added to the vaccine strain composition used from 1967 to 1971. In the period from 1971 to 1977, one vaccine strain was withdrawn and two new strains were added. Since 1978, three vaccine strains has been used continuously until the present [5] .
Since the introduction of mass pertussis vaccination in 1960, reported pertussis rates dropped substantially. However, in the mid-1990s, increased pertussis rates were reported in all age groups [6] . Consequently, in 2004, Poland introduced an additional booster dose for 6-year-old children with an acellular pertussis (aP) vaccine to prevent waning vaccine-induced immunity. Moreover, in 2016, a subsequent obligatory booster dose of the aP vaccine was introduced for 14-year-old children. Currently, Poland is the only country in Europe still using the wP vaccine in children up to 2 years old. Nevertheless, in infants and children up to 2 years old, the use of aP vaccines instead of wP vaccines is increasing as a result of parental decisions. Despite the fact that pertussis vaccination coverage of cohorts generally oscillates around 98.0-99.6 %, the epidemiology of whooping cough in recent years has changed. Currently, a high prevalence of pertussis is observed among adolescents and adults [7] . The registration of 4959 pertussis cases in 2015 (morbidity: 12.89/100 000) was found to be more than two times higher than in 2014 (2102 cases) and almost four times higher when compared with 2010 (1272 cases). In 2016, 6856 pertussis cases were registered (morbidity: 17.84/ 100 000) [8] .
In recent years, many countries (e.g. the UK, the Netherlands, the USA and Australia) have experienced notable increases in the reported cases of pertussis [4, 9] . Recent studies indicate that switching from wP vaccines to less reactive aP vaccines resulted in a higher pertussis burden because immunity induced by aP vaccines is shorter in duration of protection compared to wP vaccines [10, 11] . In countries in which aP vaccines have been used for many years, Prn-deficient isolates predominate [12] [13] [14] . It has been suggested that the emergence of Prn-deficient isolates is driven by aP vaccines [15] . Aside from the switch from wP to aP vaccines, several reasons have been suggested to explain the resurgence of pertussis in highly vaccinated populations including increased awareness of pertussis, improvement of diagnostics and better pertussis surveillance, decreased vaccine efficacy, waning vaccineinduced immunity, and pathogen adaptation to vaccination [1, 3, 16, 17] .
Genetic divergence between vaccine strains and clinical isolates has been found to be a general trend worldwide [2, [18] [19] [20] [21] [22] [23] [24] . The emergence of new antigenic variants of B. pertussis strains was regarded as a source of the decrease in vaccine efficacy [3, 25] . Therefore, monitoring genetic variations in the B. pertussis populations and studying the effect of these variations on increasing the incidence of pertussis are important for developing more effective pertussis vaccines and establishing optimized vaccination strategies. Moreover, monitoring changes in B. pertussis populations enables one to estimate the emergence and spread of new variants of isolates and is important in predicting the evolution of the B. pertussis population. Our previous studies on tracing genetic differences with PFGE and sequencing of virulencerelated genes showed that B. pertussis isolates circulating in Poland are genetically quite different to those observed elsewhere in Europe [5, 26] . To deepen our knowledge on the genetic changes driven in the B. pertussis population circulating in Poland, multi-locus variable-number tandem repeat analysis (MLVA) was applied. Additionally, the MLVA data were correlated to MLST profiling and PFGE fingerprinting to precisely identify the most successful clones that have increased in frequency over the last decade. 
METHODS

Strain collection
MLVA analysis
The analysis of the polymorphisms in six loci containing variable-number tandem-repeat sequences (VNTR1, VNTR3a, VNTR3b, VNTR4, VNTR5, VNTR6) was performed according to the methodology developed by Schouls et al. [27] . PCR products of VNTR loci were separated on a 3730xl DNA Analyzer (Applied Biosystems). The GeneScan data were analysed using Peak Scanner Software (Applied Biosystems). In order to confirm the reliability of size readings in the GeneScan analysis, reference strain Tohama I was used in each run as a control.
The assessment of the number of repeats in the PCR products was performed using an Excel The GeneScan analysis data were imported into BioNumerics version 6.6 software (Applied Maths, Belgium) and analysed. Each isolate was characterized by the MLVA profile, consisting of a specific order of numbers in the profile relating to the number of repeats at each VNTR locus in the following order: VNTR1, VNTR3a, VNTR3b, VNTR4, VNTR5 and VNTR6. A minimum-spanning tree was prepared based on the categorical clustering of MLVA profiles.
MLST
Polymorphism in the genes ptxA, ptxC, prn, tcfA, fim2, fim3 and pertussis toxin promoter ptxP for all isolates was analysed previously [26] .
PFGE analysis
Most of the isolates (139) were previously analysed by PFGE [5] . In this study, PFGE analysis was performed for 25 isolates according to the procedure described previously [5] . The PFGE profiles were analysed by using BioNumerics version 6.6 software (Applied Maths, Belgium).
Diversity index
The diversity index (DI) was calculated for MLVA, MLST and PFGE as described by Hunter and Gatson [28] .
RESULTS
MLVA
The MLVA analysis performed in this study showed a high degree of polymorphism in all six VNTR loci analysed. The greatest diversity was identified in the locus VNTR6, with eight alleles detected. The smallest degree of variation was found in the loci VNTR1 and VNTR5, for which only three alleles were found. Six, five and four alleles were detected in VNTR4, VNTR3a and VNTR3b, respectively. Almost 92 % (160/174) of isolates did not contain VNTR repeats in the locus VNTR3b.
In the study, 20 previously published (RIVM, http://mlva. net/bpertussis/) and 11 newly identified MLVA types (MTs) were detected among 174 B. pertussis isolates collected in Poland between 1959 and 2013. Additionally, two 
*New MLVA type detected in this study.
previously published and one new MLVA type were identified among the B. pertussis strains used for wP vaccine production in Poland (Tables 1 and 2 The clonal relationship between detected MTs was visualized by constructing the minimum-spanning tree based on the categorical clustering of MLVA profiles (Fig. 1) . Circles represent individual MLVA types. The radii of the circles are proportional to the number of isolates representing the MLVA type, whereas the length of the lines connecting the circles and numbers appearing on lines represents the number of VNTR loci with differences found between the combined MTs.
Among all analysed B. pertussis isolates, MT29 was found to be the most common type with a general frequency of 27.6 % (48/174); it was found in each of the four periods under study. Three other prevailing types, MT70, MT207 and MT141, were represented by 15.5 %, 9.2 % and 8. isolates under study and showed differences in the number of VNTR repeats in at least three loci (Fig. 1) .
MLST
Eleven different allelic combinations (MLST profiles) of the six genes and ptxP promoter analysed were found among 174 clinical isolates under study. The allele profile ptxA1-ptxC1-ptxP1-prn1-tcfA2-fim2-1-fim3-1 was predominant and was carried by 46 % (80/174) of the isolates analysed. Three current vaccine strains harboured the same MLST profile -ptxA2-ptxC1-ptxP1-prn1-tcfA2-fim2-1-fim3-1 (Tables 2 and S1 ).
PFGE
Altogether, 88 PFGE profiles were found among 174 analysed isolates. Obtained PFGE profiles were classified into nine PFGE groups (I, III, IVa, IVb, IVg, V, A, B and C). The largest number of isolates (40.8 %, 71/174) and three current vaccine strains were clustered in PFGE group III (Tables 2 and S1 ).
Correlation of MLVA, MLST and PFGE typing data
When we combined MLVA, MLST and PFGE typing results, we identified 55 MLVA-MLST-PFGE profiles among all of the isolates under study (Table 3) . MT141-ptxA2-ptxC1-ptxP1-prn1-tcfA2-fim2-1-fim3-1-PFGE III 6.9 % (12/174) MT29-ptxA1-ptxC1-ptxP1-prn1-tcfA2-fim2-1-fim3-1-PFGE III 5.7 % (10/174) MT29-ptxA1-ptxC1-ptxP1-prn2-tcfA2-fim2-1-fim3-1-PFGE C 5.7 % (10/174) MT273-ptxA1-ptxC1-ptxP1-prn1-tcfA2-fim2-1-fim3-1-PFGE A 5.2 % (9/174) MT207-ptxA1-ptxC1-ptxP1-prn1-tcfA2-fim2-1-fim3-1-PFGE C 4.0 % (7/174) MT29-ptxA1-ptxC1-ptxP1-prn2-tcfA2-fim2-1-fim3-1-PFGE IVg 3.4 % (6/174) [29] . Similarly, in the Netherlands, the MT29 type prevailed in the periods 1965-1972, 1989-1992 and 1996-1998 ; subsequently, from 1999, the MT27 type became dominant [30, 31] .
The MT70 type appeared in the 1970s and increased in frequency to 37.5 % in the period 2000-2013. Currently, MT70 type-carrying isolates are extremely rare in other highly vaccinated populations. In the period 1998-2012, the MT70 type was identified only once outside Poland among 466 European B. pertussis isolates studied [32] . MT70 typeharbouring isolates were found widely circulating in the UK between 1998 and 2001 [33] and in Australia in the period 1996-2005 [34] .
In the present study, we showed that only five isolates carrying the MT27 type were identified among the isolates collected in Poland in the period 2000-2013. All MT27 isolates carried ptxP3. A linkage between MT27 and ptxP3 seen in our study was also observed previously [32, 35] . Currently, the MT27 type is predominant in Europe [29, [31] [32] [33] We suspect that the low frequency of the MT27 type among isolates collected in Poland might be connected with the continued usage of the wP vaccine. In the Philippines, where the wP vaccine is still used, no isolates from the period 2012-2014 carried the MT27 type [37] . Similarly, among B. pertussis isolates collected between 1950-2007 in China, where wP was routinely used in the immunization programme up to 2012, the MT27 type was detected in only two B. pertussis isolates from 1955 and 1965 [38] . Taken together, it appears that B. pertussis isolates carrying the MT27 type are distinctly predominant in countries where aP vaccines are routinely and exclusively used. In contrast, in countries where wP vaccines are still in use, such as Poland, the Philippines and China (before 2012), MLVA types other than MT27 are predominant. This may indicate that the evolution of B. pertussis might be specifically driven by the type of pertussis vaccine used in pertussis immunization programmes.
As summarized by Sealey [9] , the introduction of pertussis vaccination initiated a new selective pressure on the circulating B. pertussis isolates that promoted evolution towards vaccine escape. A number of studies demonstrated that vaccine-mediated immunity is regarded as the driving force for the evolution of B. pertussis [9, 15, [39] [40] [41] [42] . wP vaccination effectively controlled circulating B. pertussis isolates resembling vaccine strains while enabling the emergence and widespread of new populations of B. pertussis [3, 41, 43, 44] .
Our study demonstrated that the MLVA profiles of B. pertussis isolates currently circulating in Poland are different from the profiles carried by the current vaccine strains. Isolates carrying the MT141 type were very frequent in the Table 3 . cont.
MLVA-MLST-PFGE profile Frequency
MT277-ptxA1-ptxC1-ptxP1-prn2-tcfA2-fim2-1-fim3-1-PFGE III 0.6 % (1/174) MT278-ptxA1-ptxC1-ptxP1-prn3-tcfA2-fim2-1-fim3-1-PFGE III 0.6 % (1/174) MT319-ptxA1-ptxC1-ptxP1-prn2-tcfA2-fim2-1-fim3-1-PFGE* 0. In summary, the results of the study are quite clear and are in line with our previous results showing that the B. pertussis population in Poland is different from isolates circulating in other European countries [5, 26] . On one hand, the specific evolution of the B. pertussis population in Poland might have resulted from constant wP vaccine usage; while on the other hand, unusual changes in wP vaccine strain compositions until 1978 and specificity of the Polish wP vaccine might have also been involved in driving the unique genetic structure of the B. pertussis population.
Similarly to studies performed by Advani [18] and Bowden [45] , we found that PFGE has higher discriminatory potential in B. pertussis typing than MLVA and MLST. However, when MLST and MLVA were combined, the discriminatory power increased. We think that MLVA-MLST may be a useful typing approach which can be used as alternative to PFGE to trace genetic differences efficiently.
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